Literature DB >> 1848854

Structure-activity studies of vasoactive intestinal polypeptide.

M O'Donnell1, R J Garippa, N C O'Neill, D R Bolin, J M Cottrell.   

Abstract

This report explores the potential side-chain functional groups required for interaction of the bronchodilator neuropeptide, vasoactive intestinal peptide (VIP), with its receptor. The binding affinity and biological activity of native VIP have been found to be sensitive to the removal of amino- and carboxyl-terminal residues. This data suggests that elements within the entire primary sequence of the VIP molecule appear to be necessary for recognition by VIP receptors. The introduction of alanine residues substituted into the VIP molecule is utilized to probe for side-chain functional groups that are crucial for eliciting high receptor binding affinity in vitro and high biological potency in vivo. The VIP pharmacophore appears to be identical in guinea pig lung and human lung and consists of multiple binding sites most likely involving positions Asp3, Phe6, Thr7, Tyr10, Tyr22, and Leu23. These findings could be exploited to enhance the biological potency of VIP by increasing the binding energy at these positions.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1848854

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  6 in total

1.  Modulation of adenovirus vector tropism via incorporation of polypeptide ligands into the fiber protein.

Authors:  Natalya Belousova; Valentina Krendelchtchikova; David T Curiel; Victor Krasnykh
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

2.  Evidence for a direct interaction between the Thr11 residue of vasoactive intestinal polypeptide and Tyr184 located in the first extracellular loop of the VPAC2 receptor.

Authors:  Ingrid Nachtergael; Pascale Vertongen; Ingrid Langer; Jason Perret; Patrick Robberecht; Magali Waelbroeck
Journal:  Biochem J       Date:  2003-03-15       Impact factor: 3.857

3.  Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery.

Authors:  U Bickel; T Yoshikawa; E M Landaw; K F Faull; W M Pardridge
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-01       Impact factor: 11.205

4.  Bronchodilation by an inhaled VPAC(2) receptor agonist in patients with stable asthma.

Authors:  A Lindén; L Hansson; A Andersson; M Palmqvist; P Arvidsson; C-G Löfdahl; P Larsson; J Lötvall
Journal:  Thorax       Date:  2003-03       Impact factor: 9.139

Review 5.  Structure-activity relationship of vasoactive intestinal peptide (VIP): potent agonists and potential clinical applications.

Authors:  Satomi Onoue; Shingen Misaka; Shizuo Yamada
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-01-03       Impact factor: 3.000

6.  Agnathan VIP, PACAP and their receptors: ancestral origins of today's highly diversified forms.

Authors:  Stephanie Y L Ng; Billy K C Chow; Jun Kasamatsu; Masanori Kasahara; Leo T O Lee
Journal:  PLoS One       Date:  2012-09-05       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.